R&D | March 28, 2026
AbbVie stakes claim to redefine skin disease treatment at Global Dermatology Summit
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
The study included four independent genetic substudies targeting obesity caused by heterozygous variants in the POMC/PCSK1, LEPR, SRC1 (NCOA1), and SH2B1 genes
The partnership is designed to close the gap between classroom learning and real-world pharmaceutical practice
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
COVIRIX Medical says its broad-spectrum antiviral portfolio has already shown positive virology results against key pandemic threats
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
Subscribe To Our Newsletter & Stay Updated
